Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pirfenidone.

Joseph Lasky1

  • 1Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-9, New Orleans, LA 70112, USA. jlasky@tulane.edu

Idrugs : the Investigational Drugs Journal
|April 2, 2004
PubMed
Summary
This summary is machine-generated.

Pirfenidone is an antifibrotic drug being developed to treat fibrotic diseases like kidney, liver, and lung fibrosis. It also shows potential for treating multiple sclerosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic Signature-Guided Depletion of Intermediate Alveolar Epithelial Cells Ameliorates Pulmonary Fibrosis in Mice.

Research square·2025
Same author

Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.

EJHaem·2024
Same author

Hospitalization Rates in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Registry.

American journal of respiratory and critical care medicine·2024
Same author

Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.

American journal of respiratory and critical care medicine·2023
Same author

Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia.

Frontiers in oncology·2023
Same author

Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.

The Lancet. Haematology·2023

Area of Science:

  • Pharmacology
  • Fibrosis Research
  • Neurology

Background:

  • Fibrotic diseases involve excessive tissue scarring.
  • Pirfenidone is an established antifibrotic agent.
  • Multiple sclerosis is a chronic neurological condition.

Purpose of the Study:

  • To explore the therapeutic potential of pirfenidone.
  • To investigate pirfenidone's efficacy in various fibrotic conditions.
  • To assess pirfenidone's application in multiple sclerosis treatment.

Main Methods:

  • Drug development pipeline analysis.
  • Review of preclinical and clinical data.
  • Pharmacological profiling of pirfenidone.

Main Results:

Related Experiment Videos

  • Pirfenidone demonstrates antifibrotic properties.
  • Potential applications identified for renal, liver, and pulmonary fibrosis.
  • Emerging evidence suggests utility in multiple sclerosis.

Conclusions:

  • Pirfenidone is a promising candidate for treating fibrotic diseases.
  • Further research is warranted for its application in multiple sclerosis.
  • Pirfenidone's antifibrotic mechanism offers broad therapeutic potential.